Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LYL1 basic helix-loop-helix family member (LYL1) is a transcription factor belonging to the basic helix-loop-helix (bHLH) protein family and is involved in the regulation of cell fate during hematopoiesis and vascular development[5][6]. The encoded protein binds DNA in a sequence-specific manner and dimerizes with other bHLH factors to regulate gene expression[2][5]. LYL1 plays a crucial role in blood vessel maturation and the maintenance of hematopoietic stem and progenitor cells[3][5]. Chromosomal translocations involving the LYL1 locus have been associated with acute lymphoblastic leukemia[5][6]. LYL1 interacts with other transcriptional regulators such as TCF3 and NFKB1[2], and has significant roles in developmental lineage commitment and cancer biology[3]. No approved drugs directly targeting LYL1 are documented, and its primary therapeutic interest is its implication in hematological malignancies[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LYL1 basic helix-loop-helix family member (LYL1).